
CANF
Can Fite Biopharma Ltd
- Overview
- Forecast
- Valuation
- Earnings

Line
|

Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.730
Open
0.710
VWAP
--
Vol
499.85K
Mkt Cap
2.85B
Low
0.6725
Amount
--
EV/EBITDA(TTM)
--
Total Shares
4.99M
EV
7.09M
EV/OCF(TTM)
--
P/S(TTM)
9.58
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q3
150.00K
-23.47%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Can-Fite BioPharma Ltd. (CANF) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -34.54%.
Revenue Estimates for FY2025
No Change

0.00%
In Past 3 Month
Stock Price
Go Down

-34.54%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Can Fite Biopharma Ltd (CANF.A) is -1.35, compared to its 5-year average forward P/E of -0.77. For a more detailed relative valuation and DCF analysis to assess Can Fite Biopharma Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A
5Y Average PE
-0.77
Current PE
-1.35
Overvalued PE
4.22
Undervalued PE
-5.75
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A
5Y Average EV/EBITDA
0.22
Current EV/EBITDA
0.08
Overvalued EV/EBITDA
0.83
Undervalued EV/EBITDA
-0.39
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A
5Y Average PS
16.00
Current PS
0.00
Overvalued PS
30.66
Undervalued PS
1.34
Financials
Annual
Quarterly
FY2023Q4
YoY :
-21.32%
155.00K
Total Revenue
FY2023Q4
YoY :
-40.51%
-1.83M
Operating Profit
FY2023Q4
YoY :
-45.28%
-1.65M
Net Income after Tax
FY2023Q4
0.00
EPS - Diluted
FY2024Q4
YoY :
0.00%
100.00
Gross Profit Margin - %
FY2024Q4
YoY :
-0.21%
-1.13K
FCF Margin - %
FY2024Q4
YoY :
+9.69%
-1.17K
Net Margin - %
FY2024Q4
N/A
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
CANF News & Events
Events Timeline
2025-07-28 (ET)
2025-07-28
07:10:50
Can-Fite BioPharma announces group from UCLA demonstrate Piclidenoson efficacy

2025-05-05 (ET)
2025-05-05
08:19:52
Can-Fite raises $175M to date for namodenoson, piclidenoson development

2025-04-17 (ET)
2025-04-17
08:57:23
Can-Fite BioPharma says medical centers seek authorization for namodenoson

Sign Up For More Events
Sign Up For More Events
News
9.0
06-16NewsfilterCan-Fite to Present Phase IIa Pancreatic Cancer Study Progress During Partnering Meetings at the 2025 BIO International Convention in Boston
9.0
06-16NASDAQ.COMCan-Fite To Present Phase IIa Pancreatic Cancer Study Update At BIO 2025
8.5
05-05NewsfilterCan-Fite Has Raised $175 Million in Total to Date for the Development of Namodenoson and Piclidenoson, Advancing into Pivotal Phase 3 Trials in Liver Cancer and Psoriasis
Sign Up For More News
People Also Watch
FAQ

What is Can Fite Biopharma Ltd (CANF) stock price today?
The current price of CANF is 0.7135 USD — it has increased 1.71 % in the last trading day.

What is Can Fite Biopharma Ltd (CANF)'s business?

What is the price predicton of CANF Stock?

What is Can Fite Biopharma Ltd (CANF)'s revenue for the last quarter?

What is Can Fite Biopharma Ltd (CANF)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Can Fite Biopharma Ltd (CANF)'s fundamentals?

How many employees does Can Fite Biopharma Ltd (CANF). have?
